The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes among patients with resected high-risk melanoma (AJCC7 IIIB, IIIC, M1a, M1b) randomized to low- or high-dose adjuvant Ipilimumab (ipi) versus high-dose interferon alfa-2b (HDI): Health-related quality of life (HRQL) analysis of ECOG-ACRIN E1609.
 
Ahmad A. Tarhini
Consulting or Advisory Role - Array BioPharma; BioNTech; Bristol-Myers Squibb; Genentech/Roche; HUYA Bioscience International; Immunocore; Incyte; Merck; Newlink Genetics; Novartis; OncoSec; Pfizer/EMD Serono; Sanofi/Regeneron
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); GreenPeptide (Inst); Incyte (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Prometheus (Inst); Prometheus (Inst)
 
Yue Zheng
No Relationships to Disclose
 
Sandra J. Lee
Employment - NantWorks (I)
Stock and Other Ownership Interests - NantWorks (I)
Consulting or Advisory Role - Roche/Genentech
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Compass Therapeutics; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Uma Rao
No Relationships to Disclose
 
Gary Irvin Cohen
Stock and Other Ownership Interests - Abbvie; Celgene; Nymox
Honoraria - Amgen
 
Vernon K. Sondak
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Merck/Schering Plough; Novartis; Pfizer; Polynoma; Regeneron; Replimune
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Polynoma; Replimune
 
John M. Kirkwood
Consulting or Advisory Role - Amgen; Amgen (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Checkmate Pharmaceuticals (Inst); Elsevier; Immunocore; Immunocore (Inst); Iovance Biotherapeutics; Merck (Inst); Novartis
Research Funding - Immunocore (Inst); Merck (Inst); Prometheus (Inst)
 
Lynne I. Wagner
Consulting or Advisory Role - Celgene
Travel, Accommodations, Expenses - Celgene